A clinical study of MK-8527 in people with HIV-1 (MK-8527-004)

2023-503682-39-00 Protocol MK-8527-004 Human pharmacology (Phase I) - Other Ended

Start 13 Nov 2023 · End 20 Feb 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol MK-8527-004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 26
Countries 1
Sites 1

HIV-1 (Human Immunodeficiency Virus Type 1)

Key facts

Sponsor
Merck Sharp & Dohme LLC
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
13 Nov 2023 → 20 Feb 2024
Decision date (initial)
2023-06-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-503682-39-00
WHO UTN
U1111-1287-7295

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

HIV-1 (Human Immunodeficiency Virus Type 1)

VersionLevelCodeTermSystem organ class
20.1 LLT 10068341 HIV-1 infection 10021881

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Sharp & Dohme LLC

Sponsor organisation
Merck Sharp & Dohme LLC
Address
126 East Lincoln Avenue
City
Rahway
Postcode
07065-4607
Country
United States

Scientific contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Russ Carstens

Public contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Russ Carstens

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ended 5 1
Rest of world
South Africa
21

Investigational sites

Romania

1 site · Ended
Institutul National De Boli Infectioase Prof.Dr.Matei Bals
Institutul National De Boli Infectioase Prof.Dr.Matei Bals ‘Phase I Unit: Pavilion 1, Wards 2,3,4', Strada Dr. Calistrat Grozovici Nr. 1, 021105, Bucharest

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2023-11-13 2024-01-31 2023-11-16 2024-01-31

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-01 Romania Acceptable
2023-06-13
2023-06-16
2 SUBSTANTIAL MODIFICATION SM-1 2023-08-10 Romania Acceptable
2023-10-11
2023-11-13